Обзор современных возможностей эндокринной терапии гормонозависимых злокачественных опухолей молочной железы

Автор: Усеинова А.Н., Калиберденко В.Б., Марьяненко С.П., Аль-нсоур Д.М., Коренкова А.А.

Журнал: Сибирский онкологический журнал @siboncoj

Статья в выпуске: 3 т.23, 2024 года.

Бесплатный доступ

Цель исследования – представить современные данные о фармакотерапии гормонозависимого рака молочной железы (гРМЖ) и рассмотреть возможность внедрения в практику новых лекарственных средств в составе гормонотерапии РМЖ. Материал и методы. Проведен поиск литературных источников в базах данных Pubmed, Springer, Cochrane Library и др. За последние 10 лет найдено 80 публикаций, посвященных изучению фармакологических свойств различных групп лекарственных препаратов при лечении гРМЖ на разных стадиях, из которых 49 включены в данный обзор.

Рак молочной железы, химиотерапия, селективные модуляторы рецепторов эстрогена, селективный деструктор рецепторов эстрогена, доказательная медицина

Короткий адрес: https://sciup.org/140305922

IDR: 140305922 | DOI: 10.21294/1814-4861-2024-23-3-159-167

Список литературы Обзор современных возможностей эндокринной терапии гормонозависимых злокачественных опухолей молочной железы

International agency for research on cancer [Internet]. World Health Organization. [cited 2023 Nov 15]. URL: https://gco.iarc.fr.
Rak molochnoi zhelezy [Internet]. Vsemirnaya organizatsiya zdravookhraneniya [cited 2023 Nov 18]. URL: https://www.who.int/ru/news-room/fact-sheets/detail/breast-cancer.
Cardoso F., Paluch-Shimon S., Senkus E., Curigliano G., Aapro M.S., André F., Barrios C.H., Bergh J., Bhattacharyya G.S., Biganzoli L., Boyle F., Cardoso M.J., Carey L.A., Cortés J., El Saghir N.S., Elzayat M., Eniu A., Fallowfield L., Francis P.A., Gelmon K., Gligorov J., Haidinger R., Harbeck N., Hu X., Kaufman B., Kaur R., Kiely B.E., Kim S.B., Lin N.U., Mertz S.A., Neciosup S., Offersen B.V., Ohno S., Pagani O., Prat A., Penault-Llorca F., Rugo H.S., Sledge G.W., Thomssen C., Vorobiof D.A., Wiseman T., Xu B., Norton L., Costa A., Winer E.P. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020; 31(12): 1623-49. https://doi.org/10.1016/j.annonc.2020.09.010.
Takada M., Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chin Clin Oncol. 2020; 9(3): 32. https://doi.org/10.21037/cco-20-123.
Rugo H.S., Rumble R.B., Macrae E., Barton D.L., Connolly H.K., Dickler M.N., Fallowfield L., Fowble B., Ingle J.N., Jahanzeb M., Johnston S.R., Korde L.A., Khatcheressian J.L., Mehta R.S., Muss H.B., Burstein H.J. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016; 34(25): 3069-103. https://doi.org/10.1200/JCO.2016.67.1487.
Shagufta Ahmad I. Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives. Eur J Med Chem. 2018; 143: 515-31. https://doi.org/10.1016/j.ejmech.2017.11.056.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015; 386(10001): 1341-52. https://doi.org/10.1016/S0140-6736(15)61074-1.
Hong J., Huang J., Shen L., Zhu S., Gao W., Wu J., Huang O., He J., Zhu L., Chen W., Li Y., Chen X., Shen K. A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis. BMC Cancer. 2020; 20(1): 663. https://doi.org/10.1186/s12885-020-07156-x.
Lainé M., Fanning S.W., Chang Y.F., Green B., Greene M.E., Komm B., Kurleto J.D., Phung L., Greene G.L. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021; 23(1): 54. https://doi.org/10.1186/s13058-021-01431-w.
Goetz M.P., Bagegni N.A., Batist G., Brufsky A., Cristofanilli M.A., Damodaran S., Daniel B.R., Fleming G.F., Gradishar W.J., Graff S.L., Grosse Perdekamp M.T., Hamilton E., Lavasani S., Moreno-Aspitia A., O’Connor T., Pluard T.J., Rugo H.S., Sammons S.L., Schwartzberg L.S., Stover D.G., Vidal G.A., Wang G., Warner E., Yerushalmi R., Plourde P.V., Portman D.J., Gal-Yam E.N. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. Ann Oncol. 2023; 34(12): 1141-51. https://doi.org/10.1016/j.annonc.2023.09.3104.
Motlani G., Motlani V., Acharya N., Dave A., Pamnani S., Somyani D., Agrawal S. Novel Advances in the Role of Selective Estrogen Receptor Modulators in Hormonal Replacement Therapy: A Paradigm Shift. Cureus. 2023; 15(11). https://doi.org/10.7759/cureus.49079.
Perrone F., Gallo C., De Laurentiis M., Bisagni G., Arpino G., Sarobba M.G., Riccardi F., Russo A., Del Mastro L., Cogoni A.A., Cognetti F., Gori S., Frassoldati A., Amoroso D., Laudadio L., Moscetti L., Montemurro F., Nuzzo F., Carlini P., De Placido S., On Behalf of GIM Investigators. Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial. Ann Oncol. 2017; 35. https://doi.org/10.1200/JCO.2017.35.15_suppl.515.
Garcia-Martinez L., Zhang Y., Nakata Y., Chan H.L., Morey L. Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021; 12(1): 1786. https://doi.org/10.1038/s41467-021-22024-3.
Glück S. Consequences of the Convergence of Multiple Alternate Pathways on the Estrogen Receptor in the Treatment of Metastatic Breast Cancer. Clin Breast Cancer. 2017; 17(2): 79-90. https://doi.org/10.1016/j.clbc.2016.08.004.
Akça K.T., Demirel M.A., Süntar I. The Role of Aromatase Enzyme in Hormone Related Diseases and Plant-Based Aromatase Inhibitors as Therapeutic Regimens. Curr Top Med Chem. 2022; 22(3): 229-46. https://doi.org/10.2174/1568026621666211129141631.
Wang Y., Jing F., Wang H. Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence. Adv Ther. 2022; 39(2): 862-91. https://doi.org/10.1007/s12325-021-01924-2.
Zucchini G., Geuna E., Milani A., Aversa C., Martinello R., Montemurro F. Clinical utility of exemestane in the treatment of breast cancer. Int J Womens Health. 2015; 7: 551-63. https://doi.org/10.2147/IJWH.S69475.
Finn R.S., Crown J.P., Lang I., Boer K., Bondarenko I.M., Kulyk S.O., Ettl J., Patel R., Pinter T., Schmidt M., Shparyk Y., Thummala A.R., Voytko N.L., Fowst C., Huang X., Kim S.T., Randolph S., Slamon D.J. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015; 16(1): 25-35. https://doi.org/10.1016/S1470-2045(14)71159-3.
Braal C.L., Jongbloed E.M., Wilting S.M., Mathijssen R.H.J., Koolen S.L.W., Jager A. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs. 2021; 81(3): 317-31. https://doi.org/10.1007/s40265-020-01461-2.
Notaro U.S., Huber E., Stassi A.F., Ormaechea N.E., Chiaraviglio J.A., Baravalle M.E., Ortega H.H., Rey F., Salvetti N.R. Estrogens receptors, nuclear coactivator 1 and ligand-dependent corepressor expression are altered early during induced ovarian follicular persistence in dairy cattle. Theriogenology. 2023; 210: 17-27. https://doi.org/10.1016/j.theriogenology.2023.07.004.
Brufsky A.M., Dickler M.N. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. Oncologist. 2018; 23(5): 528-39. https://doi.org/10.1634/theoncologist.2017-0423.
Dickler M.N., Tolaney S.M., Rugo H.S., Cortés J., Diéras V., Patt D., Wildiers H., Hudis C.A., O’Shaughnessy J., Zamora E., Yardley D.A., Frenzel M., Koustenis A., Baselga J. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017; 23(17): 5218-24. https://doi.org/10.1158/1078-0432.CCR-17-0754. Erratum in: Clin Cancer Res. 2018; 24(21): 5485.
Gnant M., Dueck A.C., Frantal S., Martin M., Burstein H.J., Greil R., Fox P., Wolff A.C., Chan A., Winer E.P., Pfeiler G., Miller K.D., Colleoni M., Suga J.M., Rubovsky G., Bliss J.M., Mayer I.A., Singer C.F., Nowecki Z., Hahn O., Thomson J., Wolmark N., Amillano K., Rugo H.S., Steger G.G., Hernando Fernández de Aránguiz B., Haddad T.C., Perelló A., Bellet M., Fohler H., Metzger Filho O., Jallitsch-Halper A., Solomon K., Schurmans C., Theall K.P., Lu D.R., Tenner K., Fesl C., DeMichele A., Mayer E.L; PALLAS groups and investigators. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022; 40(3): 282-93. https://doi.org/10.1200/JCO.21.02554.
Rugo H.S., Im S.A., Joy A.A., Shparyk Y., Walshe J.M., Sleckman B., Loi S., Theall K.P., Kim S., Huang X., Bananis E., Mahtani R., Finn R.S., Diéras V. Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3. Breast. 2022; 66: 324-31. https://doi.org/10.1016/j.breast.2022.11.005.
Xu B., Hu X., Li W., Sun T., Shen K., Wang S., Cheng Y., Zhang Q., Cui S., Tong Z., Geng C., Song E., Huang C.S., Sriuranpong V., Ngan R.K.C., Chia Y.H., Wang X., Zhao H. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptorpositive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4. Eur J Cancer. 2022; 175: 236-45. https://doi.org/10.1016/j.ejca.2022.08.012.
Hortobagyi G.N., Stemmer S.M., Burris H.A., Yap Y.S., Sonke G.S., Hart L., Campone M., Petrakova K., Winer E.P., Janni W., Conte P., Cameron D.A., André F., Arteaga C.L., Zarate J.P., Chakravartty A., Taran T., Le Gac F., Serra P., O’Shaughnessy J. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022; 386(10): 942-50. https://doi.org/10.1056/NEJMoa2114663.
Ji J., Zhang Z., He X., Pan G., Li G., Lv J., Xu Y., Xie M., Feng J., Wang W., Liu B., Ma J., Wang X. A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6. Anticancer Drugs. 2023; 34(7): 803-15. https://doi.org/10.1097/CAD.0000000000001475.
Cristofanilli M., Rugo H.S., Im S.A., Slamon D.J., Harbeck N., Bondarenko I., Masuda N., Colleoni M., DeMichele A., Loi S., Iwata H., O’Leary B., André F., Loibl S., Bananis E., Liu Y., Huang X., Kim S., Lechuga Frean M.J., Turner N.C. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clin Cancer Res. 2022; 28(16): 3433-42. https://doi.org/10.1158/1078-0432.CCR-22-0305.
Johnston S.R.D., Harbeck N., Hegg R., Toi M., Martin M., Shao Z.M., Zhang Q.Y., Martinez Rodriguez J.L., Campone M., Hamilton E., Sohn J., Guarneri V., Okada M., Boyle F., Neven P., Cortés J., Huober J., Wardley A., Tolaney S.M., Cicin I., Smith I.C., Frenzel M., Headley D., Wei R., San Antonio B., Hulstijn M., Cox J., O’Shaughnessy J., Rastogi P.; monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, NodePositive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020; 38(34): 3987-98. https://doi.org/10.1200/JCO.20.02514.
Johnston S.R.D., Toi M., O’Shaughnessy J., Rastogi P., Campone M., Neven P., Huang C.S., Huober J., Jaliffe G.G., Cicin I., Tolaney S.M., Goetz M.P., Rugo H.S., Senkus E., Testa L., Del Mastro L., Shimizu C., Wei R., Shahir A., Munoz M., San Antonio B., André V., Harbeck N., Martin M.; monarchE Committee Members. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023; 24(1): 77-90. https://doi.org/10.1016/S1470-2045(22)00694-5.
Sledge G.W. Jr, Toi M., Neven P., Sohn J., Inoue K., Pivot X., Burdaeva O., Okera M., Masuda N., Kaufman P.A., Koh H., Grischke E.M., Conte P., Lu Y., Barriga S., Hurt K., Frenzel M., Johnston S., Llombart-Cussac A. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2020; 6(1): 116-24. https://doi.org/10.1001/jamaoncol.2019.4782.
Moreau-Bachelard C., Robert M., Gourmelon C., Bourbouloux E., Patsouris A., Frenel J.S., Campone M. Evaluating everolimus for the treatment of breast cancer. Expert Opin Pharmacother. 2023; 24(10): 1105-11. https://doi.org/10.1080/14656566.2023.2214677.
Prat A., Brase J.C., Cheng Y., Nuciforo P., Paré L., Pascual T., Martínez D., Galván P., Vidal M., Adamo B., Hortobagyi G.N., Baselga J., Ciruelos E. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. Oncologist. 2019; 24(7): 893-900. https://doi.org/10.1634/theoncologist.2018-0407.
Juric D., Rodon J., Tabernero J., Janku F., Burris H.A., Schellens J.H.M., Middleton M.R., Berlin J., Schuler M., Gil-Martin M., Rugo H.S., Seggewiss-Bernhardt R., Huang A., Bootle D., Demanse D., Blumenstein L., Coughlin C., Quadt C., Baselga J. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. J Clin Oncol. 2018; 36(13): 1291-9. https://doi.org/10.1200/JCO.2017.72.7107. Erratum in: J ClinOncol. 2019; 37(4): 361. Erratum in: J Clin Oncol. 2019; 37(4): 361.
André F., Ciruelos E., Rubovszky G., Campone M., Loibl S., Rugo H.S., Iwata H., Conte P., Mayer I.A., Kaufman B., Yamashita T., Lu Y.S., Inoue K., Takahashi M., Pápai Z., Longin A.S., Mills D., Wilke C., Hirawat S., Juric D.; SOLAR-1 Study Group.Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20): 1929-40. https://doi.org/10.1056/NEJMoa1813904.
Andrikopoulou A., Chatzinikolaou S., Panourgias E., Kaparelou M., Liontos M., Dimopoulos M.A., Zagouri F. The emerging role of capivasertib in breast cancer. Breast. 2022; 63: 157-67. https://doi.org/10.1016/j.breast.2022.03.018.
Shagufta, Ahmad I., Mathew S., Rahman S. Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer. RSC Med Chem. 2020; 11(4): 438-54. https://doi.org/10.1039/c9md00570f.
Llombart-Cussac A., Pérez-García J.M., Bellet M., Dalenc F., Gil-Gil M., Ruíz-Borrego M., Gavilá J., Sampayo-Cordero M., Aguirre E., Schmid P., Marmé F., Di Cosimo S., Gligorov J., Schneeweiss A., Albanell J., Zamora P., Wheatley D., Martínez-de Dueñas E., Amillano K., Malfettone A., Cortés J.; PARSIFAL Steering Committee and Trial Investigators. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021; 7(12): 1791-9. https://doi.org/10.1001/jamaoncol.2021.4301. Erratum in: JAMA Oncol.2021; 7(11): 1729.
Ma C.X., Luo J., Freedman R.A., Pluard T.J., Nangia J.R., Lu J., Valdez-Albini F., Cobleigh M., Jones J.M., Lin N.U., Winer E.P., Marcom P.K., Thomas S., Anderson J., Haas B., Bucheit L., Bryce R., Lalani A.S., Carey L.A., Goetz M.P., Gao F., Kimmick G., Pegram M.D., Ellis M.J., Bose R. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clin Cancer Res. 2022; 28(7): 1258-67. https://doi.org/10.1158/1078-0432.CCR-21-3418.
Huang J., Huang P., Shao X.Y., Sun Y., Lei L., Lou C.J., Ye W.W., Chen J.Q., Cao W.M., Huang Y., Zheng Y.B., Wang X.J., Chen Z.H. Efficacy of fulvestrant 500mg in Chinese postmenopausal women with advanced/ recurrent breast cancer and factors associated with prolonged time-totreatment failure: A retrospective case series. Medicine (Baltimore). 2020; 99(29). https://doi.org/10.1097/MD.0000000000020821.
Bidard F.C., Kaklamani V.G., Neven P., Streich G., Montero A.J., Forget F., Mouret-Reynier M.A., Sohn J.H., Taylor D., Harnden K.K., Khong H., Kocsis J., Dalenc F., Dillon P.M., Babu S., Waters S., Deleu I., García Sáenz J.A., Bria E., Cazzaniga M., Lu J., Aftimos P., Cortés J., Liu S., Tonini G., Laurent D., Habboubi N., Conlan M.G., Bardia A. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022; 40(28): 3246-56. https://doi.org/10.1200/JCO.22.00338. Erratum in: J Clin Oncol. 2023; 41(23): 3962.
Bardia A., Chandarlapaty S., Linden H.M., Ulaner G.A., Gosselin A., Cartot-Cotton S., Cohen P., Doroumian S., Paux G., Celanovic M., Pelekanou V., Ming J.E., Ternès N., Bouaboula M., Lee J.S., Bauchet A.L., Campone M. AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. Nat Commun. 2022; 13(1): 4116. https://doi.org/10.1038/s41467-022-31668-8.
Campone M., Bidard F.C., Neven P., Wang L., Ling B., Dong Y., Paux G., Herold C., De Giorgi U. AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer. Breast Cancer Res. 2023; 25(1): 141. https://doi.org/10.1186/s13058-023-01740-2.
Hurvitz S.A., Bardia A., Quiroga V., Park Y.H., Blancas I., Alonso-Romero J.L., Vasiliev A., Adamchuk H., Salgado M., Yardley D.A., Berzoy O., Zamora-Auñón P., Chan D., Spera G., Xue C., Ferreira E., Badovinac Crnjevic T., Pérez-Moreno P.D., López-Valverde V., Steinseifer J., Fernando T.M., Moore H.M., Fasching P.A.; coopERA Breast Cancer study group. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023; 24(9): 1029-41. https://doi.org/10.1016/S1470-2045(23)00268-1. Erratum in: Lancet Oncol. 2023; 24(11).
Smith I., Robertson J., Kilburn L., Wilcox M., Evans A., Holcombe C., Horgan K., Kirwan C., Mallon E., Sibbering M., Skene A., Vidya R., Cheang M., Banerji J., Morden J., Sidhu K., Dodson A., Bliss J.M., Dowsett M. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 2020; 21(11): 1443-54. https://doi.org/10.1016/S1470-2045(20)30458-7. Erratum in: Lancet Oncol. 2020; 21(12).
Jhaveri K., Juric D., Yap Y.S., Cresta S., Layman R.M., Duhoux F.P., Terret C., Takahashi S., Huober J., Kundamal N., Sheng Q., Balbin A., Ji Y., He W., Crystal A., De Vita S., Curigliano G. A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2021; 27(21): 5760-70. https://doi.org/10.1158/1078-0432.CCR-21-1095.
Qin H., Zhang Y., Lou Y., Pan Z., Song F., Liu Y., Xu T., Zheng X., Hu X., Huang P. Overview of PROTACs Targeting the Estrogen Receptor: Achievements for Biological and Drug Discovery. Curr Med Chem. 2022; 29(22): 3922-44. https://doi.org/10.2174/0929867328666211110101018.
Puyang X., Furman C., Zheng G.Z., Wu Z.J., Banka D., Aithal K., Agoulnik S., Bolduc D.M., Buonamici S., Caleb B., Das S., Eckley S., Fekkes P., Hao M.H., Hart A., Houtman R., Irwin S., Joshi J.J., Karr C., Kim A., Kumar N., Kumar P., Kuznetsov G., Lai W.G., Larsen N., Mackenzie C., Martin L.A., Melchers D., Moriarty A., Nguyen T.V., Norris J., O’Shea M., Pancholi S., Prajapati S., Rajagopalan S., Reynolds D.J., Rimkunas V., Rioux N., Ribas R., Siu A., Sivakumar S., Subramanian V., Thomas M., Vaillancourt F.H., Wang J., Wardell S., Wick M.J., Yao S., Yu L., Warmuth M., Smith P.G., Zhu P., Korpal M. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ErαWT and ERαMUT Breast Cancer. Cancer Discov. 2018; 8(9): 1176-93. https://doi.org/10.1158/2159-8290.CD-17-1229.
Gu G., Tian L., Herzog S.K., Rechoum Y., Gelsomino L., Gao M., Du L., Kim J.A., Dustin D., Lo H.C., Beyer A.R., Edwards D.G., Gonzalez T., Tsimelzon A., Huang H.J., Fernandez N.M., Grimm S.L., Hilsenbeck S.G., Liu D., Xu J., Alaniz A., Li S., Mills G.B., Janku F., Kittler R., Zhang X.H., Coarfa C., Foulds C.E., Symmans W.F., Andò S., Fuqua S.A.W. Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021; 40(5): 997-1011. https://doi.org/10.1038/s41388-020-01563-x. Erratum in: Oncogene. 2022; 41(3): 460.

Еще

Статья научная